Floatz logo

Orelabrutinib

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The First Affiliated Hospital with Nanjing Medical UniversitySmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

202 Active assets in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
Etoposide
Weill Medical College of Cornell University
Phase 2BBB
Chlorambucil
Ascentage Pharma Group Inc.
Phase 4BBB
Lisaftoclax
Henan Cancer Hospital
Phase 3BBB
Irinotecan
IGM Biosciences, Inc.
Phase 2BBB
Prednisone
AstraZeneca
Phase 3BBB

View all 50 →

Same molecule, other indications

Orelabrutinib is also rated in:

marginal zone lymphomaActive
BBB
Indicative · Phase 4
73 / 100
View asset →
primary central nervous system lymphomaActive
BB
Indicative · Phase 3
70 / 100
View asset →
mantle cell lymphomaActive
B
Indicative · Phase 3
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →